Milestone Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Regulatory and Corporate Update

May 13, 2024

https://www.globenewswire.com/news-release/2024/05/13/2880300/0/en/Milestone-Pharmaceuticals-Reports-First-Quarter-2024-Financial-Results-and-Provides-Regulatory-and-Corporate-Update.html

– NDA for etripamil in PSVT resubmitted in 1Q 2024
– Cash resources as of March 31, 2024 expected to fund operations into 2026
– Dialogue with FDA to finalize Phase 3 protocol for etripamil in AFib-RVR is progressing

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.